Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Asia Spotlight: India Case Study – Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On

Executive Summary

Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.

You may also be interested in...

On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales

MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names

Western Companies' Perspectives On Emerging Markets: Execution Trumps Strategy - PharmAsia Summit

SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco

Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share

MUMBAI - Marketing of patented and branded drugs is a relatively new concept in India but going by the initial strategies put into play by multinational companies - most notably for the DPP-4 inhibitors Januvia (sitagliptin), Galvus (vildagliptin) and Onglyza (saxagliptin) - it has all the ingredients of blowing up into an all out war in the race to capture the mind recall of doctors

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts